Myeloid Therapeutics’ name no longer fits its pipeline. Having expanded beyond the eponymous myeloid cells, the biotech has rebranded as Create Medicines and committed to an R&D strategy that spans in ...
Recent advances in cancer research have underscored the critical role of myeloid cells in shaping tumor microenvironments (TME), influencing tumor progression, immune evasion, and therapeutic ...
With its pipeline expanding beyond its initial focus on in vivo programming of myeloid cells, for which the company took its initial name, Myeloid Therapeutics has rebranded as Create Medicines and ...
Triggering receptors expressed on myeloid cells (TREMs) are a cell surface receptor family found on granulocytes, monocytes, macrophages, and dendritic cells—as well as other myeloid cells in general.
Amphista to initiate its first clinical trial for AMX-883, a potent, orally bioavailable DCAF16-dependent degrader of BRD9, for acute myeloid ...
In the clinical battle against leukemia, recent breakthroughs in chimeric antigen receptor T cells (CAR T) have given patients and doctors an unprecedented weapon. CAR T cell therapy has demonstrated ...
Anatomy explorers have charted a new path myeloid cells use to access the brain. On 3 June in Neuron, scientists led by Lindsay Hohsfield and Kim Green, both at the University of California, Irvine, ...
Super immunodeficient mice such as the NOG-EXL and NSG-SGM3 combine severe immunodeficiency with transgenic expression of human myeloid-stimulatory cytokines. These mouse strains support an improved ...
Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results